Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Diffuse Large B-cell Lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by the World Health Organization~   a. subtyping is required for DLBCL~2. No prior therapy for diagnosis of DLBCL~3. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of equal to or greater than 1 lesion that measures \>1.5 cm in the longest diameter and \> 1.0 cm in the longest perpendicular diameter assessed by CT or MRI) or bone marrow involvement~4. Eastern Cooperative Oncology Group performance score of 0-2~5. Life expectancy of at least 6 months~6. No history of medication dependent diabetes mellitus~7. Required screening laboratory data (within 4 weeks prior to start of study drug) -~Exclusion Criteria:~1. Patients already on any class of anti-diabetic medication including metformin, insulin analogues, sulfonylureas, thiazolidinediones (TZDs) and the incretin-based therapies or clear need for therapeutic intervention based on fasting blood glucose~2. Known histological transformation from indolent non-Hodgkins Lymphoma (NHL) or chronic lymphocytic leukemia (CLL) to an aggressive form of NHL (ie, Richter transformation)~3. Double or triple hit lymphomas~4. Known active cent4ral nervous system or leptomeningeal lymphoma~5. Presence of known intermediate or high-grade myelodysplastic syndrome~6. History of a non-lymphoid malignancy within the last 3 years (see protocol for exceptions)~7. Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study~8. Ongoing, drug-induced liver injury, chronic active Hepatitis C Virus (HCV), chronic active Hepatitis B Virus (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.~9. HIV positive~10. Ongoing inflammatory bowel disease~11. Ongoing alcohol or drug addiction~12. Pregnancy~13. History of prior allogeneic bone marrow progenitor cell or solid organ transplantation.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-CHOP with Metformin (Type: EXPERIMENTAL): Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues